Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis

Petrelli, Fausto; Ferrara, Roberto; Signorelli, Diego; Ghidini, Antonio; Proto, Claudia; Roudi, Raheleh; Sabet, Mehrdad Nasrollahzadeh; Facelli, Sara; Garassino, Marina Chiara; Luciani, Andrea; Roviello, Giandomenico

doi:10.2217/imt-2020-0224

Cited by 36 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized controlled trials have confirmed that adding ICIs to chemotherapy can improve patient prognosis. 10 Mutations in proto-oncogenes and tumor suppressor genes probably affect the treatment response and survival of lung cancer patients. Exploring the genetic background of different populations is of great significance to predict lung cancer patients’ response to immunotherapies.…”

Section: Discussionmentioning

confidence: 99%

A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer

Zhang

et al. 2021

CMAR

View full text Add to dashboard Cite

Objective To evaluate the value of serum complement component 1q (C1q) levels in predicting the efficacy of combined immunotherapy in patients with lung cancer. Methods A total of 42 patients with lung cancer who received combined immunotherapy in the cancer center of Renmin Hospital of Wuhan University were included in this study. The clinical data of serum C1q and lactate dehydrogenase (LDH) levels before and three weeks after immunotherapy were collected. Results Response evaluation showed that the number of patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) was 0 (0%), 26 (61.9%), 14 (33.3%), and 2 (4.8%), respectively. The CR/PR group (patients with CR or PR) showed higher p C1q (C1q level before immunotherapy) and i C1q (C1q level 3 weeks after immunotherapy) than the SD/PD group (patients with SD or PD). The LDH reduction (96.2%) and C1q increment (84.6%) in the CR/PR group 3 weeks after immunotherapy were higher than those of the SD/PD group, and the differences were statistically significant. Logistic regression analysis indicated that p C1q, i C1q, and LDH level trends 3 weeks after the treatment were significantly correlated to the efficacy of combined immunotherapy with odds ratios of 8.185, 5.500, and 0.031, respectively. Conclusion High C1q levels before immunotherapy and increased C1q levels and decreased LDH levels 3 weeks afterward suggest good therapeutic effects of combined immunotherapy in patients with lung cancer. Serum C1q levels have certain clinical significance in predicting the efficacy of combined immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer

Zhang

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…During the last few years, cancer immunotherapy has demonstrated promising results with different types of tumors [9][10][11][12]. In particular, with the introduction of immune checkpoint inhibitor (ICI)-targeted immunotherapy, the immunotolerant tumor microenvironment can be overcome by reactivating T cells, enhancing anti-tumor immunity, and eliminating tumor cells more effectively [13].…”

Section: Introductionmentioning

confidence: 99%

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas

Porcellato

Mecocci

Brachelente

et al. 2021

Animals

View full text Add to dashboard Cite

In horses, penile squamous cell carcinomas (epSCCs) are among the most common cutaneous neoplastic lesions. These tumors usually arise in benign lesions such as viral plaques and papillomas frequently induced by Equus caballus papillomavirus type 2 (EcPV2) infection. In the last decade, the introduction of immune checkpoint inhibitors (ICI) for the treatment of human cancers has demonstrated promising results. Among the most commonly targeted pathways, there is PD-1/PD-L1 and CTLA-4. The aim of this study is to investigate the expression of the PD-1/PD-L1 pathway and CTLA-4 in the tumor microenvironment of epSCCs to assess the feasibility of an immunotherapeutic approach. Twenty equine epithelial tumors were retrospectively selected and submitted to RT-qPCR for PD-1 and PD-L1 genes. After testing antibodies cross-reactivity by western blotting, immunohistochemistry for PD-L1 and CTLA-4 was performed. Results from RT-qPCR demonstrated that 3/20 cases expressed the PD-L1 gene, whereas the PD-1 gene was not detected. Immunohistochemical positivity for PD-L1 was found only in one case. CTLA-4-positive cells were observe in all cases but were few (Mdn = 4.8; IQR = 2.3–7.1 cells/HPF). In this study group, PD-1/PD-L1 and CTLA-4 do not appear to be highly expressed and therefore the use of ICI in epSCCs may not have promising rates of response.

show abstract

“…The findings support the superiority of ICIs over docetaxel in pretreated NSCLC patients, and suggest that anti-PD-1 inhibitors may have a minor advantage over anti-PD-L1 inhibitors 2. Petrelli et al confirmed in their meta-analysis that there is moderate evidence that adding ICIs to chemotherapy improves overall survival (OS) when compared with chemotherapy alone 3. However, in a review of Zhu et al put forward different opinions.…”

Section: Introductionmentioning

confidence: 89%

Potential key roles of tumour budding: a representative malignant pathological feature of non-small cell lung cancer and a sensitive indicator of prognosis

Zhang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo investigate the relationship between tumour budding, clinicopathological characteristics of patients and prognosis in non-small cell lung cancer.Study designA retrospective study was used.ParticipantsWe selected 532 patients with non-small cell lung cancer from China, including 380 patients with adenocarcinoma and 152 with squamous cell carcinoma.Primary and secondary outcome measuresTumour budding was visible using H&E staining as well as pancytokeratin staining. The count data and measurement data were compared using the χ2 test and the t-test, respectively. The overall survival rate was the follow-up result. The survival curves were drawn using the Kaplan-Meier method, and the differences between groups were analysed using the log-rank method. The independent prognostic factor of patients with lung cancer was determined using a multivariate Cox proportional hazard model.ResultsIn patients with lung adenocarcinoma, there was a correlation between tumour budding and spread through air spaces (OR 36.698; 95% CI 13.925 to 96.715; p<0.001), and in patients with squamous cell carcinoma, tumour budding state was closely related to the peritumoural space (OR 11.667; 95% CI 4.041 to 33.683; p<0.001). On Cox regression analysis, multivariate analysis showed that tumour budding, pleural and vascular invasion, spread through air spaces, tumour size, lymph node metastasis, and tumour node metastasis stage were independent risk factors of prognosis for patients with non-small cell lung cancer.ConclusionsAs an effective and simple pathological diagnostic index, it is necessary to establish an effective grading system in the clinical diagnosis of lung cancer to verify the value of tumour budding as a prognostic indicator. We hope that this analysis of Chinese patients with non-small cell lung cancer can provide useful reference material for the continued study of tumour budding.

show abstract

Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis

Cited by 36 publications

References 31 publications

A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer

A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas

Potential key roles of tumour budding: a representative malignant pathological feature of non-small cell lung cancer and a sensitive indicator of prognosis

Contact Info

Product

Resources

About